Loading
Abdera Therapeutics engineered antibodies that carry a radioactive isotope to cancer cells, tuning how long they circulate so more radiation reaches the tumour and less reaches healthy tissue. Its first medicine targets a protein on small cell lung cancer.
Abdera Therapeutics, based in Vancouver and Menlo Park, California, developed antibody-based radiopharmaceuticals using its ROVEr antibody engineering platform, which tunes pharmacokinetic properties so that alpha- or beta-emitting isotopes can be matched to targets with a wide range of antigen expression. Its lead programme targets DLL3 for small cell lung cancer and other solid tumours and was advancing toward the clinic at launch; founding partners were adMare BioInnovations and AbCellera. The company emerged in April 2023 with USD 142 million in combined Series A and B financing, the Series A led by Versant Ventures and Amplitude Ventures and the USD 110 million Series B led by venBio Partners with Viking Global Investors, Qiming Venture Partners USA and RTW Investments. Its phase 1 trial of 225Ac-ABD147 in small cell lung cancer and large cell neuroendocrine carcinoma of the lung (NCT06736418) started in March 2025 and, according to its ClinicalTrials.gov record last updated in April 2026, had stopped recruiting after enrolling 17 patients. In the same month a related DLL3 imaging study led by the investigator Thomas Hope, with Abdera as collaborator, was withdrawn before enrolling anyone, with the reason given as sponsor funding.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Led by venBio Partners; the company's launch release reports USD 142 million in combined Series A and B financing | 2023 | $110M | endpoints.news |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Endpoints News, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Small-cell lung cancer.
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares DLL3, Small-cell lung cancer.
Shares DLL3, Small-cell lung cancer.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/